Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry a deep trial record: STEP studied semaglutide for weight management (NEJM 2021), SURMOUNT studied tirzepatide for weight management (NEJM 2022), and SURMOUNT-OSA studied tirzepatide for obstructive sleep apnea (NEJM 2024)
Dipeptidyl peptidase IV in human T lymphocytes
For best results, take on an empty stomach
The peptide binds to GHRH receptors and activates receptors on pituitary somatotrophs, initiating cAMP-mediated intracellular signaling that stimulates physiological GH secretion and produces secondary IGF-1 elevation through hepatic stimulation
That window powered the rapid growth of telehealth GLP-1 platforms
